Company News
Compass Pathways Secures FDA Rolling Review
FDA granted Compass Pathways a rolling NDA review for its synthetic psilocybin drug COMP360 targeting treatment‑resistant depression.
COMP360 was also selected for the Commissioner’s National Priority
